Sun Pharma Discontinues Psoriasis and Eczema Drug SCD-044 After Phase 2 Trial Failures
Sun Pharma's experimental oral drug SCD-044 (Vibozilimod) failed to meet primary endpoints in Phase 2 trials for both psoriasis and atopic dermatitis, missing the 75% improvement target in PASI and EASI scores at 16 weeks.
Sun Pharma's Sonidegib Shows Promise Across Multiple Cancer Indications Beyond Basal Cell Carcinoma
Sonidegib phosphate (Odomzo), currently approved for locally advanced basal cell carcinoma, is being investigated for multiple additional cancer indications including gastroesophageal junction adenocarcinoma and medulloblastoma.